Financial Performance - In 2025, the company achieved total revenue of 464.53 million yuan, representing a year-on-year growth of 12.43% [2] - The net profit attributable to the parent company was 51.15 million yuan, a decrease of 1.76% compared to the previous year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 23.66 million yuan, significantly increasing from 5.08 million yuan in 2024 [2] - By the end of 2025, total assets reached 1,993.07 million yuan, an increase of 5.25% from the beginning of the reporting period [2] - The equity attributable to the parent company was 1,802.17 million yuan, up 3.47% from the beginning of the reporting period [2] Business Development - The company has deepened its overseas expansion, with overseas revenue growing by over 40%, accounting for more than 30% of total revenue, validating the effectiveness of its international strategy [3] - The high-end pressure monitoring radiofrequency ablation catheter has been commercialized in over 20 countries, and the cryoablation system has received EU certification, with successful applications in Germany, Turkey, and Greece [3] - The company actively participated in major international academic conferences, showcasing its "electric fire ice" solution, which has garnered significant industry attention and recognition [3] Domestic Market Focus - The company continues to focus on high-end surgical breakthroughs and product innovation, with a steady increase in three-dimensional surgical volumes [4] - The usage of pressure monitoring radiofrequency ablation catheters increased by over 70% year-on-year, accelerating the domestic replacement process of high-end electrophysiology devices [4] - In November 2025, the company launched the PulseMagic? TrueForce? disposable pressure monitoring cardiac pulsed electric field ablation catheter, becoming the first in China to feature saline infusion capabilities [4] Profitability Factors - The net profit attributable to the parent company increased by 365.73% year-on-year, primarily due to revenue growth and cost reduction efforts [5]

证券之星消息，2月11日南向资金减持1.7万股高视医疗（02407.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持6.17万股。近20个交易日中，获南向资金减持的有20天，累计净减持20.38万 股。截至目前，南向资金持有高视医疗（02407.HK）565.27万股，占公司已发行普通股的3.81%。 高视医疗科技有限公司是一家主要从事眼科医疗器械及耗材的研发、制造及销售的投资控股公司。该公 司经营四个分部。自有产品分部开发及生产手术设备及相关配套软件、内光透镜、眼科疾病诊断及治疗 设备以及相关配套耗材。经销分部销售其他眼科医疗器械制造商生产的多功能诊断设备、眼底诊断、手 术及治疗设备以及相关配套耗材。技术服务分部提供保修服务、维护服务及售后服务所用耗材。其他分 部主要包括授出知识产权权限，以及提供临床研究组织相关服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Qiming Medical-B (02500.HK) by 23,000 shares on February 11, with a total net reduction of 111,500 shares over the past five trading days and 636,000 shares over the past twenty trading days [1] - As of now, southbound funds hold 52,088,100 shares of Qiming Medical-B, accounting for 11.8% of the company's total issued ordinary shares [1] Group 2 - Qiming Medical Co., Ltd. is primarily engaged in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices and auxiliary instruments for treating heart valve diseases [1] - The company's product line includes devices for interventional treatment of aortic valve, pulmonary valve, mitral valve, tricuspid valve diseases, as well as systems for radiofrequency ablation for hypertrophic cardiomyopathy and ultrasound ablation systems for renal denervation in hypertension [1] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolism protection device, with operations in both domestic and overseas markets [1]

经济观察网拜尔德医疗(BDMD.OQ)股价于2026年2月11日大幅下跌8.69%，收于0.83美元，创下历史新 低。当日开盘价为0.95美元，最高触及0.95美元，最低下探至0.80美元，振幅达16.51%。全天成交量为 214,270股，成交额为179,488美元，换手率为0.58%。 行业板块情况 当日，其所属的美股医疗器械板块微涨0.07%，而纳斯达克指数微跌0.04%。拜尔德医疗的走势与行业 及大盘出现明显分化，可能反映了其自身的特定风险。 以上内容基于公开资料整理，不构成投资建议。 公司基本面 公开资料显示，该公司在当日未发布重大利空公告。股价破位下行可能受多重因素影响。公司市盈率 (TTM)为-7.55，显示其处于持续亏损状态，且年初至今累计跌幅已达38.96%，市场信心明显不足。 资金面情况 当日成交额仅约17.95万美元，流动性较低，少量卖单即容易引发股价大幅波动。 ...

Core Viewpoint - Southbound funds have reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 1.72 million shares on February 11, with a total net reduction of 2.70 million shares over the past five trading days [1] Group 1: Shareholding Changes - In the last 20 trading days, southbound funds have increased their holdings on 14 days, resulting in a total net increase of 22.13 million shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.16% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Group 1 - The research center in the Yangtze River Delta is collaborating with Zhikou Technology (Quzhou) Co., Ltd. to provide professional testing for motorcycle shift actuators, enhancing product quality and accelerating R&D iterations [1] - The four-province marginal radio equipment testing center, operational since August last year, serves over twenty local enterprises and has become an "accelerator" for industrial innovation [1] - Zhejiang Jingjing Technology Co., Ltd., a key project that landed in Quzhou last year, has commenced production of medical endoscopes and has a full order schedule extending into the second half of the year [1] Group 2 - The continuous optimization of Quzhou's innovation ecosystem and the enhancement of policy support are driving a wave of innovation [2] - The municipal science and technology bureau has launched a "R&D Offensive" service action, focusing on promoting R&D expense collection and tax deduction policies for industrial enterprises [2] - Future strategies will include optimizing the innovation ecosystem through precise policy supply and service connections to activate the vitality of enterprises, universities, and research institutions [2]

经济观察网碧迪医疗(BDX.N)于2026年2月11日股价上涨4.72%，收盘报179.78美元。此次上涨主要与公 司最新财报表现、分析师评级调整及市场情绪改善相关。 业绩经营情况 根据2025财年第四季度财报，公司营收达58.9亿美元，同比增长8%，调整后每股收益为3.96美元，高于 华尔街平均预期。全年营收218.4亿美元，同比增长8.2%，盈利能力持续改善。财报显示生命科学业务 呈现复苏迹象，诊断解决方案业务在季度内重返正增长轨道。 机构观点 2026年2月10日至11日，多家机构更新评级。TD Cowen将目标价从183美元上调至189美元，维持"持 有"评级；花旗维持"买入"评级，目标价232美元为当前机构预测中的较高水平。市场对公司在生命科学 业务出售后的聚焦策略表示关注。 行业政策与环境 以上内容基于公开资料整理，不构成投资建议。 医疗器械板块近期受政策及创新主题催化。2026年2月10日中国国际医疗设备与器械交易平台上线，推 动行业全球化预期。同时，公司自身现金流稳健，2025财年自由现金流达26.7亿美元，支撑股息支付。 ...

Core Insights - The report emphasizes the focus on undervalued and performance-recovering sectors within the medical services and consumer segments, predicting a fundamental improvement in 2026 [4]. Group 1: Investment Strategy - The report maintains an "outperform" rating for the sector, indicating a positive outlook for the medical and consumer-related segments [2]. - Key areas of focus include medical services, pharmacies, and home medical devices, which are expected to see performance recovery and valuation improvements in 2026 [4]. Group 2: Sector Analysis - Medical services are anticipated to recover due to improved supply structure and consumer environment, with leading companies expected to show positive earnings guidance for 2026 [4]. - The pharmacy sector has shown significant marginal improvement since Q3 2025, with leading companies experiencing quarterly performance enhancements [4]. - Home medical devices are expected to benefit from increased product penetration and domestic production rates, contributing to sustained performance growth [4]. Group 3: Notable Companies - The report highlights specific companies to watch, including Aier Eye Hospital, Yuyue Medical, and Yifeng Pharmacy, which are positioned for growth in their respective segments [4]. - The investment portfolio for February 2026 includes a mix of A-share and H-share companies, such as Mindray Medical, WuXi AppTec, and Kangfang Biotech, indicating a diversified approach to investment [4]. Group 4: Market Performance - The medical sector outperformed the broader market in January 2026, with a 3.14% increase compared to the 1.49% rise of the CSI 300 index [10]. - Sub-sectors such as medical services and medical devices showed significant gains, with respective increases of 8.82% and 5.28% [17]. Group 5: Macro Data - In 2025, the pharmaceutical manufacturing industry reported a total revenue of 24,870 billion yuan, reflecting a slight decline of 1.2% year-on-year, while total profits increased by 2.7% [9]. - The retail sales of pharmaceuticals reached 7,294 billion yuan, with a year-on-year growth of 1.8%, indicating a stable demand in the market [9].

Core Viewpoint - Goldman Sachs increased its stake in Times Angel (06699) by purchasing 226,200 shares at an average price of HKD 72.15 per share, totaling approximately HKD 16.32 million, resulting in a new holding of about 10.32 million shares, representing 6.04% of the company [1] Group 1 - Goldman Sachs' purchase of 226,200 shares indicates a bullish sentiment towards Times Angel [1] - The average purchase price of HKD 72.15 per share reflects the current market valuation of Times Angel [1] - The total investment of approximately HKD 16.32 million signifies a significant commitment by Goldman Sachs to the company [1]

证券之星消息，截至2026年2月11日收盘，开立医疗(300633)报收于26.8元，下跌1.29%，换手率 0.75%，成交量3.23万手，成交额8727.49万元。 2月11日的资金流向数据方面，主力资金净流入109.89万元，占总成交额1.26%，游资资金净流入826.22 万元，占总成交额9.47%，散户资金净流出936.11万元，占总成交额10.73%。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 近5日资金流向一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、 ...